Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER-2 Positive Malignant Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07132242
What this trial is testing

SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer With HER2 Positive
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 84
Testing effectiveness (Phase 2)Study completedNCT01594177
What this trial is testing

Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy

Who this might be right for
Unilateral HER2 Positive Breast Cancer
GBG Forschungs GmbH 65
Large-scale testing (Phase 3)Study completedNCT01419197
What this trial is testing

Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 602
Not applicableUnknownNCT05880160
What this trial is testing

Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction

Who this might be right for
CardiotoxicityHER2-positive Breast CancerHeart Failure+1 more
University College, London 90
Not applicableStudy completedNCT00968682
What this trial is testing

CADY Study ICORG 08-01

Who this might be right for
Breast CancerCardiac Toxicity
Cancer Trials Ireland 480
Testing effectiveness (Phase 2)Ended earlyNCT05555251
What this trial is testing

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Metastatic Breast Cancer+2 more
BioInvent International AB 18
Not applicableStudy completedNCT05367739
What this trial is testing

Real World Study on the Efficacy and Safety of Anti-HER2 Therapy

Who this might be right for
Breast NeoplasmsHER2-positive Breast Cancer
Hunan Cancer Hospital 200
Early research (Phase 1)Ended earlyNCT05553522
What this trial is testing

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Who this might be right for
Brain MetastasesHER2-positive Breast Cancer
Baptist Health South Florida 1
Large-scale testing (Phase 3)UnknownNCT02404051
What this trial is testing

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerBreast CancerHormone Receptor Positive Tumor+2 more
Consorzio Oncotech 745
Large-scale testing (Phase 3)Looking for participantsNCT06992882
What this trial is testing

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)

Who this might be right for
HER2-positive Breast Cancer
Fudan University 2,306
Testing effectiveness (Phase 2)Study completedNCT02789657
What this trial is testing

Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.

Who this might be right for
Breast Cancer
Brown University 32
Not applicableLooking for participantsNCT06805812
What this trial is testing

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

Who this might be right for
Breast AdenocarcinomaBreast Cancer Stage IVBreast Cancer, Metastatic+38 more
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 3,500
Not applicableUnknownNCT03756064
What this trial is testing

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Who this might be right for
Breast CancerNeoplasm, BreastBreast Diseases
Zhejiang Cancer Hospital 100
Testing effectiveness (Phase 2)Study completedNCT01494662
What this trial is testing

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 140
Not applicableActive Not RecruitingNCT07498400
What this trial is testing

Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer

Who this might be right for
Breast Cancer (Triple Negative Breast Cancer (TNBC))Breast Cancer
Xijing Hospital 216
Testing effectiveness (Phase 2)Looking for participantsNCT05582499
What this trial is testing

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Who this might be right for
Breast NeoplasmBreast CancerBreast Tumors+7 more
Fudan University 716
Very early researchUnknownNCT05411432
What this trial is testing

Clinical Study of 68Ga Labeled HER2 Affibody Analogues

Who this might be right for
HER2-positive Breast Cancer and Gastric Cancer
Xijing Hospital 56
Testing effectiveness (Phase 2)Study completedNCT01669239
What this trial is testing

Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 83
Testing effectiveness (Phase 2)UnknownNCT05018702
What this trial is testing

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Who this might be right for
HER2-positive, Metastatic Breast Cancer
Fudan University 32
Large-scale testing (Phase 3)Not Yet RecruitingNCT07239271
What this trial is testing

Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant Therapy of De-escalation and Escalation for HER2-Positive Breast Cancer Based on Multi-Omics Response Evaluation Model

Who this might be right for
Patients With HER2-positive Breast Cancer (BC) Suitable for Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2,000
Next Page